Daily weight-loss tablets are widening the market for GLP-1 treatments and raising Big Pharma’s growth hopes.
Analysts expect the sector to reach about $200bn by the early 2030s as easier-to-take pills attract new users.
Novo Nordisk launched the first oral Wegovy for weight loss in the US, with prescriptions rising rapidly.
Patients switching from injections say tablets offer simpler use and steadier appetite control.
Lower prices and no need for refrigeration also make them more accessible.
Rival Eli Lilly is preparing its own pill, intensifying competition.
Injections still produce greater weight loss, so people with severe obesity will likely stay with them.
Pills are expected to draw in those who are overweight or new to treatment.
Rising global obesity, broader insurance coverage and more drug options are driving demand.
Researchers say the move from weekly jabs to daily tablets marks a pivotal moment for the industry.
